Article Details

Syndax Pharmaceuticals' (NASDAQ:SNDX) “Buy” Rating Reaffirmed at HC Wainwright

Retrieved on: 2019-03-30 07:15:00

Tags for this article:

Click the tags to see associated articles and topics

Syndax Pharmaceuticals' (NASDAQ:SNDX) “Buy” Rating Reaffirmed at HC Wainwright. View article details on hiswai:

Excerpt

<div><b>Sofinnova Ventures</b> Inc raised its position in Syndax Pharmaceuticals by 75.5% during the 3rd quarter. <b>Sofinnova Ventures</b> Inc now owns 173,112 ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up